Brief: Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
25/07/2024 06:12
July 25 (Reuters) - Ipsen SA IPN.PA :
* IPSEN AND DAY ONE ENTER INTO EXCLUSIVE EX-U.S. LICENSING
AGREEMENT TO COMMERCIALIZE TOVORAFENIB FOR THE MOST COMMON
CHILDHOOD BRAIN TUMOR
* IPSEN SA - DAY ONE RECEIVES APPROXIMATELY $111 MILLION
UPFRONT
IN CASH AND EQUITY INVESTMENT WITH UP TO APPROXIMATELY $350
MILLION IN MILESTONE PAYMENTS AND DOUBLE-DIGIT TIERED ROYALTIES
Source text for Eikon: ID:nGNX4QFjJ
Further company coverage: IPN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))